Simultaneous Activation of the δ Opioid Receptor (δOR)/Sensory Neuron-Specific Receptor-4 (SNSR-4) Hetero-Oligomer by the Mixed Bivalent Agonist Bovine Adrenal Medulla Peptide 22 Activates SNSR-4 but Inhibits δOR Signaling
Open Access
- 1 August 2006
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 70 (2) , 686-696
- https://doi.org/10.1124/mol.106.022897
Abstract
Hetero-oligomerization among G protein-coupled receptors has been proposed to contribute to signal integration. Because sensory neuron-specific receptors (SNSRs) and the opioid receptors (OR) share a common ligand, the bovine adrenal medulla peptide (BAM) 22, and have opposite effects on pain modulation, we investigated the possible consequences of δOR/SNSR-4 hetero-oligomerization on the signaling properties of both receptor subtypes. Bioluminescence resonance energy transfer revealed that the human δOR has similar propensity to homo-oligomerize and to form hetero-oligomers with human SNSR-4 when coexpressed in human embryonic kidney 293 cells. The hetero-oligomerization leads to a receptor form displaying unique functional properties. Individual activation of either δOR or SNSR-4 in cells coexpressing the two receptors led to the modulation of their respective signaling pathways; inhibition of adenylyl cyclase and activation of phospholipase C, respectively. In contrast, the δOR/SNSR-4 bivalent agonist BAM22, which could activate each receptor expressed individually, fully activated the SNSR-4-dependent phospholipase C but did not promote δOR-mediated inhibition of adenylyl cyclase in δOR/SNSR-4-coexpressing cells. Likewise, concomitant activation of the δOR/SNSR-4 hetero-oligomer by selective δOR and SNSR-4 agonists promoted SNSR-4 but not δOR signaling, revealing an agonist-dependent dominant-negative effect of SNSR-4 on δOR signaling. Furthermore, the δOR selective antagonist naltrexone trans-inhibited the SNSR-4-promoted phospholipase C activation mediated by BAM22 but not by the SNSR-4-selective agonists, suggesting a bivalent binding mode of BAM22 to the δOR/SNSR-4 hetero-oligomer. The observation that BAM22 inhibited the Leu-enkephalin-promoted cAMP inhibition in rat dorsal root ganglia neurons supports the potential physiological implication of such regulatory mechanism.This publication has 51 references indexed in Scilit:
- A Bivalent Ligand (KDAN-18) Containing δ-Antagonist and κ-Agonist Pharmacophores Bridges δ2 and κ1 Opioid Receptor PhenotypesJournal of Medicinal Chemistry, 2004
- A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ HeterodimersJournal of Medicinal Chemistry, 2004
- Oligomerization of the α1a- and α1b-Adrenergic Receptor SubtypesJournal of Biological Chemistry, 2003
- Dual Inhibition of β-Adrenergic and Angiotensin II Receptors by a Single AntagonistCirculation, 2003
- Quantitative Assessment of β1- and β2-Adrenergic Receptor Homo- and Heterodimerization by Bioluminescence Resonance Energy TransferJournal of Biological Chemistry, 2002
- Monitoring of Ligand-independent Dimerization and Ligand-induced Conformational Changes of Melatonin Receptors in Living Cells by Bioluminescence Resonance Energy TransferJournal of Biological Chemistry, 2002
- Two Defective Heterozygous Luteinizing Hormone Receptors Can Rescue Hormone ActionJournal of Biological Chemistry, 2002
- Heterologous Activation of Protein Kinase C Stimulates Phosphorylation of δ-Opioid Receptor at Serine 344, Resulting in β-Arrestin- and Clathrin-mediated Receptor InternalizationPublished by Elsevier ,2001
- Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET)Proceedings of the National Academy of Sciences, 2000
- Pro-enkephalin intermediates in bovine brain and adrenal medulla: Characterization of immunoreactive peptides related to BAM-22P and peptide FLife Sciences, 1982